Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group.
Tunbekici S, Sahin G, Ön S, Oruc A, Eryılmaz MK, Sakin A, Coskun A, Seyyar M, Uzundere FK, Kolemen E, Cabuk D, Efil SC, Demir T, Turkmen E, Ekinci F, Terzi A, Sahin TK, Guven DC, Aksoy S, Aytac A, Demirkıran Ö, Demir B, Culcuoglu I, Ersoy M, Asarkaya E, Camanlı U, Gezici B, Ozveren A, Sevınc A, Kitaplı S, Unlu A, Ozturk B, Turkel A, Dogan M, Aslan F, Yesilbas E, Kaplan E, Sakalar T, Sahin E, Emin G, Asık E, Yıldırım A, Guclu T, Ugurlu I, Kahvecioglu F, Hacıbekiroglu I, Tunbekici I, Bayram S, Kaya AO, Majidova N, Yalıcı O, Karateke M, Avcı N, Belen B, Bal H, Kınıkoglu O, Turkoz FP, Sımsek ET, Altınok O, Gunes TK, Altıntas YE, Guliyev M, Ozturk G, Erdem D, Duzkopru Y, Inal A, Guren AK, Yıldırım N, Telli TA, Danacı Y, Aydın U, Almuradova E, Yıldırım HC, Gursoy P, Sendur MAN, Goker E.
Tunbekici S, et al. Among authors: yildirim n.
Int J Cancer. 2026 Apr 1;158(7):1881-1890. doi: 10.1002/ijc.70213. Epub 2025 Oct 28.
Int J Cancer. 2026.
PMID: 41147655